Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673.
| Image |  |
|---|---|
| Description | scientific article published on 27 September 2014 |
| Author/s |
author: Richard B Lock C P Reynolds Stephen T Keir Raushan T Kurmasheva Malcolm A Smith Min H Kang Peter J. Houghton David A. Wheeler John M. Maris E Anders Kolb Hernan Carol Richard G Gorlick |
| Publication date | September 27, 2014 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |